Selective increase of iron in substantia nigra zona compacta of parkinsonian brains
- PMID: 1704426
- DOI: 10.1111/j.1471-4159.1991.tb02017.x
Selective increase of iron in substantia nigra zona compacta of parkinsonian brains
Abstract
Histochemical and biochemical determinations of total iron, iron (II), and iron (III) contents in brain regions from Parkinson's and Alzheimer's diseases have demonstrated a selective increase of total iron content in parkinsonian substantia nigra zona compacta but not in the zona reticulata. The increase of iron content is mainly in iron (III). The ratio of iron (II):iron (III) in zona compacta changes from almost 2:1 to 1:2. This change is thought to be relevant and may contribute to the selective elevation of basal lipid peroxidation in substantia nigra reported previously. Iron may be available in a free state and thus can participate in autooxidation of dopamine with the resultant generation of H2O2 and oxygen free radicals.
Similar articles
-
Brain iron and ferritin in Parkinson's and Alzheimer's diseases.J Neural Transm Park Dis Dement Sect. 1990;2(4):327-40. doi: 10.1007/BF02252926. J Neural Transm Park Dis Dement Sect. 1990. PMID: 2078310
-
Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain.J Neural Transm. 1988;74(3):199-205. doi: 10.1007/BF01244786. J Neural Transm. 1988. PMID: 3210014
-
Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration?Acta Neurol Scand Suppl. 1989;126:47-54. doi: 10.1111/j.1600-0404.1989.tb01782.x. Acta Neurol Scand Suppl. 1989. PMID: 2618593
-
Antioxidant mechanism and protection of nigral neurons against MPP+ toxicity by deprenyl (selegiline).Ann N Y Acad Sci. 1994 Nov 17;738:214-21. doi: 10.1111/j.1749-6632.1994.tb21806.x. Ann N Y Acad Sci. 1994. PMID: 7832430 Review.
-
Role of iron and iron chelation in dopaminergic-induced neurodegeneration: implication for Parkinson's disease.Ann Neurol. 1992;32 Suppl:S105-10. doi: 10.1002/ana.410320718. Ann Neurol. 1992. PMID: 1510367 Review.
Cited by
-
Longitudinal Progression Markers of Parkinson's Disease: Current View on Structural Imaging.Curr Neurol Neurosci Rep. 2018 Oct 2;18(12):83. doi: 10.1007/s11910-018-0894-7. Curr Neurol Neurosci Rep. 2018. PMID: 30280267 Free PMC article. Review.
-
Paraquat and iron exposure as possible synergistic environmental risk factors in Parkinson's disease.Neurotox Res. 2003;5(5):307-13. doi: 10.1007/BF03033150. Neurotox Res. 2003. PMID: 14715449 Review. No abstract available.
-
Evaluation of iron deposition in brain basal ganglia of patients with Parkinson's disease using quantitative susceptibility mapping.Eur J Radiol Open. 2019 Apr 29;6:169-174. doi: 10.1016/j.ejro.2019.04.005. eCollection 2019. Eur J Radiol Open. 2019. PMID: 31065578 Free PMC article.
-
New Progress on the Role of Glia in Iron Metabolism and Iron-Induced Degeneration of Dopamine Neurons in Parkinson's Disease.Front Mol Neurosci. 2018 Jan 19;10:455. doi: 10.3389/fnmol.2017.00455. eCollection 2017. Front Mol Neurosci. 2018. PMID: 29403352 Free PMC article. Review.
-
Curcumin affords neuroprotection and inhibits α-synuclein aggregation in lipopolysaccharide-induced Parkinson's disease model.Inflammopharmacology. 2018 Apr;26(2):349-360. doi: 10.1007/s10787-017-0402-8. Epub 2017 Oct 12. Inflammopharmacology. 2018. PMID: 29027056
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical